From: Magnetic nanoparticles in theranostics of malignant melanoma
Clinical trial no. | Phase | Patients | Study design | Status | Purpose | Refs |
---|---|---|---|---|---|---|
NCT00626405 | II | Unresectable stage IV melanoma | Bevacizumab + Temozolomide vs Bevacizumab + paclitaxel albumin-stabilized nanoparticle formulation + carboplatin | Completed | Treatment | [100] |
NCT00081042 | II | Unresectable stage IV melanoma | Paclitaxel albumin-stabilized nanoparticle formulation; previously chemotherapy vs chemotherapy-naive | Completed | Treatment | [101] |
NCT00738361 | II | Unresectable metastatic uveal melanoma | Paclitaxel albumin-stabilized nanoparticle formulation; single group | Completed | Treatment | Â |
NCT00404235 | II | Unresectable stage IV melanoma | Paclitaxel albumin-stabilized nanoparticle formulation; chemotherapy-naïve; single group | Completed | Treatment | [100] |
NCT02158520 | II | Unresectable stage IV melanoma | Bevacizumab + paclitaxel albumin-stabilized nanoparticle formulation vs ipilimumab | Completed | Treatment | [103] |
NCT01300533 | I | Advanced or metastatic cancer including melanoma | BIND-014: targeted docetaxel polymeric nanoparticle; single group | Completed | Treatment | [104] |
NCT02668536 | I | Melanoma and UV ray damaged skin | Standard sunscreen vs sunscreen based on bioadhesive nanoparticles | Completed | Prevention | [105] |
NCT04899908 | II | Cancer with brain metastasis including melanoma | Stereotactic radiation with vs without AGuIX gadolinium-based nanoparticles | Recruiting | Treatment | Â |
NCT03739931 | I | Advanced malignancies including melanoma | Lipid nanoparticle encapsulating mRNAs with vs without durvalumab | Recruiting | Treatment | Â |
NCT02106598 | II | Head and neck melanoma | Silica nanoparticles with fluorescent cRGDY-PEG-Cy5.5-C dots for real-time image-guided intraoperative mapping of nodal metastases | Recruiting | Diagnostic | Â |